The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
GBA ‐associated Parkinson's disease: Reduced survival and more rapid progression in a prospective longitudinal study
Abstract
Background: Parkinson's disease (PD) patients with GBA mutations show an earlier age at onset and more severe non‐motor symptoms compared with PD patients without GBA mutations. Objective: This study was undertaken to evaluate progression of motor and non‐motor symptoms in sporadic PD patients depending on the mutational GBA status. Methods: We used regression analysis to evaluate independent effects of the mutational GBA status, age at onset, age at examination, and disease duration on motor (Unified Parkinson's Disease Rating Scale [UPDRS]‐III, Hoehn and Yahr [H&Y] stage, Levodopa [ l ‐dopa]‐equivalent‐dosage) and non‐motor characteristics (cognition and mood). Disease progression was assessed prospectively over 3 years. Results: The GBA ‐associated PD patients compared with non‐mutation PD patients, although younger and with an earlier age at onset, show (1) a more rapid disease progression of motor impairment and cognitive decline and (2) reduced survival rates. Conclusions: The mutational GBA status, rather than older age and age at onset, presents an important predictor for disease progression in this specific subgroup of PD patients. © 2014 International Parkinson and Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goetz, C. G., Poewe, W., Rascol, O., Sampaio, C., Stebbins, G. T., Counsell, C., Giladi, N., Holloway, R. G., Moore, C. G., Wenning, G. K., et al. (2004) · Movement Disorders · doi:10.1002/mds.20213 · Cited by 2,347
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
Self-citationThe Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations
Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease (2003) · Movement Disorders · doi:10.1002/mds.10473 · Cited by 1,810
Mazzulli, J. R., Xu, Y.-H., Sun, Y., Knight, A. L., McLean, P. J., Caldwell, G. A., Sidransky, E., Grabowski, G. A., & Krainc, D. (2011) · Cell · doi:10.1016/j.cell.2011.06.001 · Cited by 1,341
Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease
Hoops, S., Nazem, S., Siderowf, A. D., Duda, J. E., Xie, S. X., Stern, M. B., & Weintraub, D. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c34b47 · Cited by 1,260
SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders
Litvan, I., Bhatia, K. P., Burn, D. J., Goetz, C. G., Lang, A. E., McKeith, I., Quinn, N., Sethi, K. D., Shults, C., & Wenning, G. K. (2003) · Movement Disorders · doi:10.1002/mds.10459 · Cited by 1,009
Kühner, C., Bürger, C., Keller, F., & Hautzinger, M. (2007) · Der Nervenarzt · doi:10.1007/s00115-006-2098-7 · Cited by 935
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease
Neumann, J., Bras, J., Deas, E., O'Sullivan, S. S., Parkkinen, L., Lachmann, R. H., Li, A., Holton, J., Guerreiro, R., Paudel, R., et al. (2009) · Brain · doi:10.1093/brain/awp044 · Cited by 696
The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort
Williams-Gray, C. H., Mason, S. L., Evans, J. R., Foltynie, T., Brayne, C., Robbins, T. W., & Barker, R. A. (2013) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-305277 · Cited by 681
Mutations in the Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews
Aharon-Peretz, J., Rosenbaum, H., & Gershoni-Baruch, R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033277 · Cited by 597
Cited by
Bloem, B. R., Okun, M. S., & Klein, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00218-x · Cited by 3,920
Excessive burden of lysosomal storage disorder gene variants in Parkinson’s disease
Robak, L. A., Jansen, I. E., van Rooij, J., Uitterlinden, A. G., Kraaij, R., Jankovic, J., Heutink, P., Shulman, J. M., International Parkinson’s Disease Genomics Consortium (IPDGC), Nalls, M. A., et al. (2017) · Brain · doi:10.1093/brain/awx285 · Cited by 433
Self-citationSurvival and dementia in GBA ‐associated Parkinson's disease: The mutation matters
Cilia, R., Tunesi, S., Marotta, G., Cereda, E., Siri, C., Tesei, S., Zecchinelli, A. L., Canesi, M., Mariani, C. B., Meucci, N., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24777 · Cited by 406
Genetics of Parkinson's disease: An introspection of its journey towards precision medicine
Bandres-Ciga, S., Diez-Fairen, M., Kim, J. J., & Singleton, A. B. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104782 · Cited by 370
Emerging therapies in Parkinson disease — repurposed drugs and new approaches
Elkouzi, A., Vedam-Mai, V., Eisinger, R. S., & Okun, M. S. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0155-7 · Cited by 300
The Concept of Prodromal Parkinson’s Disease
Mahlknecht, P., Seppi, K., & Poewe, W. (2015) · Journal of Parkinson's Disease · doi:10.3233/jpd-150685 · Cited by 288
GBA, Gaucher Disease, and Parkinson’s Disease: From Genetic to Clinic to New Therapeutic Approaches
Riboldi, G. M., & Di Fonzo, A. B. (2019) · Cells · doi:10.3390/cells8040364 · Cited by 274
Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's
Liu, G., Boot, B., Locascio, J. J., Jansen, I. E., Winder‐Rhodes, S., Eberly, S., Elbaz, A., Brice, A., Ravina, B., van Hilten, J. J., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24781 · Cited by 263
GBA Variants and Parkinson Disease: Mechanisms and Treatments
Smith, L., & Schapira, A. H. V. (2022) · Cells · doi:10.3390/cells11081261 · Cited by 256
Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models
Sardi, S. P., Viel, C., Clarke, J., Treleaven, C. M., Richards, A. M., Park, H., Olszewski, M. A., Dodge, J. C., Marshall, J., Makino, E., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1616152114 · Cited by 203
SMPD1 mutations, activity, and α‐synuclein accumulation in Parkinson's disease
Alcalay, R. N., Mallett, V., Vanderperre, B., Tavassoly, O., Dauvilliers, Y., Wu, R. Y. J., Ruskey, J. A., Leblond, C. S., Ambalavanan, A., Laurent, S. B., et al. (2019) · Movement Disorders · doi:10.1002/mds.27642 · Cited by 110
The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1
Gustavsson, E. K., Sethi, S., Gao, Y., Brenton, J. W., García-Ruiz, S., Zhang, D., Garza, R., Reynolds, R. H., Evans, J. R., Chen, Z., et al. (2024) · Science Advances · doi:10.1126/sciadv.adk1296 · Cited by 30
Metadata
- Authors
- Brockmann, K., Srulijes, K., Pflederer, S., Hauser, A., Schulte, C., Maetzler, W., Gasser, T., & Berg, D.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2014-12
- Volume
- 30
- Issue
- 3
- Pages
- 407-411
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W1545903791
- Cited by
- 267
- References
- 15
- FWCI
- 9.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.